Yusman Manchanda
Overview
Explore the profile of Yusman Manchanda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies I, Manchanda Y, Sloop K, Bloom S, Tan T, Tomas A, et al.
Diabetes Obes Metab
. 2025 Jan;
27(4):2294-2298.
PMID: 39888232
No abstract available.
2.
Manchanda Y, Jones B, Carrat G, Ramchunder Z, Marchetti P, Leclerc I, et al.
bioRxiv
. 2025 Jan;
PMID: 39868265
The use of incretin analogues has emerged in recent years as an effective approach to achieve both enhanced insulin secretion and weight loss in type 2 diabetes (T2D) patients. Agonists...
3.
El Eid L, Deane-Alder K, Rujan R, Mariam Z, Oqua A, Manchanda Y, et al.
bioRxiv
. 2024 Nov;
PMID: 39484598
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective therapies for type 2 diabetes (T2D) and obesity, yet patient responses are variable. Variation in the human gene might be directly linked to...
4.
Manchanda Y, Tomas A
Nat Rev Endocrinol
. 2024 Aug;
20(10):571-572.
PMID: 39174673
No abstract available.
5.
Manchanda Y, ElEid L, Oqua A, Ramchunder Z, Choi J, Shchepinova M, et al.
Sci Signal
. 2024 Jul;
17(843):eabq7038.
PMID: 38954638
Mini-G proteins are engineered, thermostable variants of Gα subunits designed to stabilize G protein-coupled receptors (GPCRs) in their active conformations. Because of their small size and ease of use, they...
6.
Oqua A, Manchanda Y, McGlone E, Jones B, Rouse S, Tomas A
J Endocrinol
. 2024 Apr;
261(3).
PMID: 38614123
The glucagon receptor family are typical class B1 G protein-coupled receptors (GPCRs) with important roles in metabolism, including the control of pancreas, brain, and liver function. As proteins with seven...
7.
Bitsi S, El Eid L, Manchanda Y, Oqua A, Mohamed N, Hansen B, et al.
Sci Adv
. 2023 May;
9(18):eadf7737.
PMID: 37134170
The glucagon-like peptide-1 receptor (GLP-1R) is a major type 2 diabetes therapeutic target. Stimulated GLP-1Rs are rapidly desensitized by β-arrestins, scaffolding proteins that not only terminate G protein interactions but...
8.
Manchanda Y, Bitsi S, Chen S, Broichhagen J, Bernardino de la Serna J, Jones B, et al.
Endocrinology
. 2023 Feb;
164(5).
PMID: 36774542
The incretin receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), are prime therapeutic targets for the treatment of type 2 diabetes (T2D) and obesity. They are expressed...
9.
Jones B, Burade V, Akalestou E, Manchanda Y, Ramchunder Z, Carrat G, et al.
Diabetes Obes Metab
. 2022 Jun;
24(11):2090-2101.
PMID: 35676825
Aims: To describe the in vitro characteristics and antidiabetic in vivo efficacy of the novel glucagon-like peptide-1 receptor agonist (GLP-1RA) GL0034. Materials And Methods: Glucagon-like peptide-1 receptor (GLP-1R) kinetic binding...
10.
McGlone E, Manchanda Y, Jones B, Pickford P, Inoue A, Carling D, et al.
Mol Metab
. 2021 Jul;
53:101296.
PMID: 34271220
Objectives: Receptor Activity-Modifying Protein 2 (RAMP2) is a chaperone protein which allosterically binds to and interacts with the glucagon receptor (GCGR). The aims of this study were to investigate the...